Causes and Consequences of Cystic Fibrosis Related Diabetes (R01)

Post Date

October 5th 2011

Application Due Date

March 20th 2012

Funding Opportunity Number

RFA-DK-11-025

CFDA Number(s)

93.847

Funding Instrument Type(s)

Grant

Funding Activity Categories

Food and Nutrition
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $1500000

• Award Range:

  $None - $None

Grant Description

This Funding Opportunity Announcement (FOA) invites applications for research project grants to study the causes and consequences of Cystic Fibrosis Related Diabetes (CFRD). CFRD is one of the most common complications of Cystic Fibrosis (CF) that occurs in almost half the patients with Cystic Fibrosis as they age. CF patients with CFRD have a higher morbidity and mortality than those who do not develop CFRD. It is not currently known why some patients develop CFRD although some genetic variants have been implicated. The mechanisms for the steeper decline in lung disease in patients with CFRD are also not understood. The NIDDK invites applications that study the etiology of CFRD in humans and animal models, as well as studies to understand the mechanisms for the increased morbidity in patients with CFRD.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-11-025.html